Product Program year 2019 Source: CMS Open Payments

Pomalyst

Drug Hematology / Oncology

NDC 59572-502-00

Open in the dashboard

General payments

$143,634

863 payments

Research payments

$2,228,238

132 payments

Through program year 2019, $143,634 in general payments and $2,228,238 in research payments were reported against Pomalyst (Hematology / Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2019 General $143,634 863
2019 Research $2,228,238 132

Breakdown

Who paid General payments · program year 2019
  1. Celgene Corporation $143,634 863 payments
Top recipients General payments · program year 2019
  1. Pranshu Bansal Hematology & Oncology · Mesa, AZ $9,824 7% · 6 payments
  2. Saulius Girnius Hematology & Oncology · Montgomery, OH $9,062 6% · 12 payments
  3. Wajahat Khan Medical Oncology · Grosse Pointe Woods, MI $7,976 6% · 7 payments
  4. Sylvia Falls Hematology & Oncology · Orland Park, IL $7,973 6% · 7 payments
  5. Gregory Smith Medical Oncology · Indianapolis, IN $7,885 5% · 10 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Hematology & Oncology Internal Medicine $86,001 60% · 262 practitioners
  2. Medical Oncology Internal Medicine $31,878 22% · 92 practitioners
  3. Internal Medicine $8,978 6% · 27 practitioners
  4. Pediatric Hematology-Oncology Pediatrics $7,010 5% · 3 practitioners
  5. Hematology Internal Medicine $5,781 4% · 22 practitioners

The top 5 of 35 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2019
  1. California $23,403 16% · 51 recipients
  2. Illinois $19,770 14% · 15 recipients
  3. Michigan $16,419 11% · 30 recipients
  4. Ohio $11,698 8% · 22 recipients
  5. Massachusetts $10,420 7% · 7 recipients

The top 5 of 43 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

79,949

Prescriptions dispensed, refills included

Drug cost

$1,738,046,814

Paid at the pharmacy, in all

Prescribers

2,972

With 11 or more claims of it

Medicare Part D drugs matched to Pomalyst, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Pomalyst Pomalidomide Same name 2,972 79,949 $1,738,046,814

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Harsh Parmar Medical Oncology NJ 421 $8,064,690 $47
Suzan Rosen Nurse Practitioner FL 323 $7,418,263 None on record
David Siegel Hematology-Oncology NJ 271 $4,997,638 None on record
Jayesh Mehta Hematology IL 234 $4,990,159 None on record
Larry Anderson Hematopoietic Cell Transplantation and Cellular Therapy TX 228 $4,864,409 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
863 general · 132 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record